Clinical trials
Lung Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting lung cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,858 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07163273RecruitingPhase 2
Alternating chemotherapy for first-line metastatic pancreatic cancer
This study tests a monthly rotation of two chemotherapy combinations (NALIRIFOX and GnP) as the first treatment for metastatic pancreatic cancer. The goal is to see if alternating the drugs helps control the cancer while reducing side effects.
Bay Shore, New YorkAges 18 years+ - NCT05546827RecruitingPhase 2
Pre-surgery radiation plus immunotherapy for mucosal melanoma
This Phase 2 trial tests giving radiation and immunotherapy before surgery for mucosal melanoma in the nose/sinuses or rectum. It may help shrink the tumor and improve outcomes while aiming to control the disease locally and in nearby areas.
Houston, TexasAges 18 years+ - NCT05876715RecruitingPhase 1/Phase 2
Testing 3 immunotherapy drugs for hard-to-remove soft tissue cancer
This Phase 1/2 study tests lurbinectedin plus two immune checkpoint medicines (ipilimumab and nivolumab) for soft tissue sarcoma that is hard to remove or has spread. It aims to see how well the combination works and how safe it is, especially for people with limited treatment options.
Santa Monica, CaliforniaAges 18–90 - NCT05689853RecruitingPhase 1/Phase 2
Testing two targeted cancer drugs for advanced solid tumors
This early-stage study tests a combination of two study medicines (AK119 plus AK112) in people with advanced solid tumors that have grown or didn’t respond to standard treatment. It may help shrink tumors or improve how long people can stay on treatment by blocking cancer-related pathways.
Beijing, Beijing MunicipalityAges 18–75 - NCT06555133RecruitingPhase 2
Study of Y-90, capecitabine, and atezolizumab for advanced colorectal cancer
This trial tests a combination of targeted radiation (Y-90), chemotherapy (capecitabine), and immunotherapy (atezolizumab) for people with colorectal cancer that has spread mainly to the liver and is no longer responding to at least two prior treatments. The goal is to see if this combination can shrink tumors or slow the disease.
Providence, Rhode IslandAges 18 years+ - NCT07373691Enrolling by invitation
Scoring system study for advanced pancreatic cancer
This study looks at a scoring system to predict how well people with advanced pancreatic cancer might do after their first chemotherapy. If you have been diagnosed with this type of cancer and are about to start or have just finished your first treatment, this study may be able to use your health information to help guide future care.
ShanghaiAges 18 years+ - NCT07146074Recruiting
Early radiation vs. observation for high-risk bone metastases
This trial tests whether giving radiation therapy early to high-risk but pain-free or nearly pain-free bone metastases can prevent future problems, compared to waiting and monitoring them. It is for people whose cancer has spread to multiple bones and who have certain risky features in those spots.
Wilrijk, AntwerpAges 18 years+ - NCT05644431Recruiting
Study of immune environment in operable stomach cancer
This study looks at how the immune system behaves in stomach or lower esophagus cancer before standard (planned) surgery. It may help researchers understand which immune features relate to outcomes and treatment response.
LyonAges 18 years+ - NCT06800196RecruitingPhase 1
Study of KNT-0916 for advanced solid tumors with FGFR2 changes
This study tests a new drug, KNT-0916, for people with advanced solid tumors that have a specific change in the FGFR2 gene. It may be an option if other treatments haven't worked or aren't available.
Guangzhou, GuangdongAges 18–75 - NCT05831033RecruitingEarly Phase 1
Your own immune T-cells to treat advanced solid tumors
This early-phase study tests a treatment made from your own tumor-fighting immune cells (TIL cells) for advanced solid cancers that have worsened or no longer respond to standard therapy. The main goal is to learn whether it is safe and whether it can shrink tumors for people who have limited options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06824155RecruitingEarly Phase 1
Radioactive drug for HER2-positive advanced cancers
This trial tests a radioactive drug (lutetium-177) that targets the HER2 protein, which is found on some cancer cells. It's for people with advanced, HER2-positive or HER2-low solid tumors that haven't responded to other treatments.
Kingswood, New South WalesAges 18 years+ - NCT06673095Recruiting
Narrow vs wide surgery for invasive skin melanoma
This trial compares two surgeries for invasive melanoma: a narrow removal versus a wider one. It aims to see if a smaller surgery works as well, which could mean less scarring and recovery time.
Davis, CaliforniaAges 18 years+ - NCT06737731RecruitingPhase 1/Phase 2
SHR-1681 for advanced solid tumors that have stopped responding to treatment
This trial tests a new drug called SHR-1681 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The goal is to see if it can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06700369Recruiting
Lowering chemo with targeted therapy for HER2+ breast cancer
This study looks at whether using targeted therapy can reduce the amount of chemotherapy needed before surgery for HER2-positive breast cancer. It aims to find a safer, equally effective treatment plan.
Beijing, Beijing MunicipalityAges Any age - NCT06812052RecruitingPhase 1
Short course radiation before surgery for retroperitoneal sarcoma
This study tests whether a short course of radiation before surgery can treat retroperitoneal sarcoma (a rare cancer in the back of the belly). It is for people whose tumor is removable and who have not had previous radiation in the same area.
Boston, MassachusettsAges 18 years+ - NCT06638034RecruitingEarly Phase 1
New imaging and radiation therapy for metastatic tumors
This trial tests a new type of imaging scan and treatment for cancers that have spread. You would first have two special scans, then you may receive a targeted radiation therapy (177Lu-FAPI-RGD) to see if it can help shrink tumors.
Beijing, Beijing MunicipalityAges 18–90 - NCT07652125Recruiting
RGL-270 vaccine plus immunotherapy for advanced lung cancer
This trial tests a new cancer vaccine (RGL-270) combined with immunotherapy drugs for advanced non-small cell lung cancer. The vaccine is designed to train your immune system to recognize and fight your specific cancer.
Guangzhou, Other (Non U.s.)Ages 18 years+ - NCT05985798RecruitingPhase 3
Immunotherapy plus TACE vs. Targeted Therapy plus TACE for Advanced Liver Cancer
This trial is testing a combination of two immunotherapy drugs (sintilimab and bevacizumab) plus a procedure called TACE (chemoembolization) against a targeted therapy pill (lenvatinib) plus TACE for people with advanced liver cancer. The goal is to see which approach works better to shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT06615349Recruiting
Digital monitoring for palliative care patients
This trial tests whether using a smartphone app to track your symptoms and health data can improve care and quality of life for people with serious illnesses who are receiving palliative care.
Zurich, Canton of ZurichAges 18 years+ - NCT07377045RecruitingPhase 1
New combo for advanced pancreatic cancer
This trial tests a new drug (OMTX705) combined with standard chemotherapy (gemcitabine/nab-paclitaxel) and an immunotherapy (tislelizumab) for people with advanced pancreatic cancer. It may be an option if you have had little or no prior chemotherapy.
Boston, MassachusettsAges 18 years+ - NCT05410145RecruitingPhase 1/Phase 2
Study drug for advanced KRAS G12C solid tumors
This trial tests D3S-001 (alone or with other treatments) in people with advanced solid cancers that have a KRAS G12C mutation. It’s mainly aimed at early safety and learning whether the treatment can shrink or control tumors.
Orange, CaliforniaAges 18 years+ - NCT06603844RecruitingPhase 1/Phase 2
Study of CRB-601-01 for advanced solid tumors
This study tests a new drug, CRB-601-01, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and can help shrink tumors.
Birmingham, AlabamaAges 18 years+ - NCT05472259RecruitingPhase 2
Testing two chemotherapy combos for metastatic pancreatic cancer
This Phase 2 study compares two chemotherapy combinations to treat metastatic pancreatic cancer that has progressed after gemcitabine (with or without Abraxane). It aims to see which combination works better and is tolerable for people with measurable disease.
Antwerp, AntwerpAges 18 years+ - NCT05978050RecruitingPhase 3
Nimotuzumab plus paclitaxel for recurring stomach cancer
This Phase 3 trial tests whether adding nimotuzumab (an anti-EGFR antibody) to paclitaxel can improve outcomes for people with stomach or stomach-junction cancer that has returned and spread. It targets tumors with high EGFR (“EGFR high” on a pathology test) to see if this combination works better than standard treatment.
Guangzhou, GuangdongAges 18–75
Hear when a new Lung Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,858 recruiting lung cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.